Could be that someone is trying to trigger stop losses by forcing the price below the last placing. I suspect the majority of shareholders are in for the long term give the risk/reward profile of the share. If I wasn't so overweight, I would be tempted to top up in my dealing account. However, I will review things in the new tax year and if it remains at these low levels, I will consider topping up with next years ISA allowance.
you are right Jiminy that in theory there is not much they can tell us ..the trial is randomised , double blind ..so we have to wait till the the end of the trial to know the outcome that will translate , or not , into big bucks . However any news of a licensing deal, as was clearly advertised by the management as a strong possibility , would send the price moving up..the size of the re-rating would of course depend on the upfront monies , and the overall package value . To think that no one will react to that event if it occurs, is delusional
The people invested here expect the trial to be successful, we already think it's safe due to phase 2. so for the next 9ish months they can only tell us it's safe or not, I can't see people pilling in here for a while yet.
News will land whenever it lands, what would it matter now anyway, if it was 10-20p higher? Would anyone be selling, I'm here until after approval (hopefully!) We know they are in talks, as per the placing. We know the trials are on track. Hoping for a rise in a couple of others, then I'll be definitely buying a few more here. This is an opportunity right now. 26 patients in total completed next month, with another 50 patients with only 12 more weeks. I'm delighted with how this has been run over the past 14-15 months
This has been a discussion about the value here, unfortunately aim is not too kind to pharma, unlike nasdaq . Whether it's the science, timeframe or resource at the end. Who knows. I do believe further value is coming next month when another 28 patients complete the trial. Of course any further advancements on pipeline or licensing will change the dynamics here also.
I honestly believe that both imm and mtfb will change people's attitudes towards bio on aim, when they see what happens to both in the next twelve months - i think both will be massive
This is the most promising company in a Phase 3 trial on AIM - along with MTFB - and I'm surprised the price isn't shooting up in anticipation, especially considering that if successful it can be applied to other huge areas of unmet need.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.